These three entrepreneurs have a lot up their sleeves for 2019. Courtesy images

3 Houston innovators to know this week

Who's Who

This week starts in one year and ends in the next, and InnovationMap has three inspiring entrepreneurs to lead you into 2019. All three are behind Houston startups that are planning for big growth in the upcoming year. So, read their stories and get familiar with their names and faces — they aren't going anywhere.

Ben Johnson, founder and CEO of Apartment Butler

Ben Johnson's business idea turned into a growing company making the lives of apartment dwellers easier. Courtesy of Apartment Butler

Ben Johnson has his own master plan. He'd work as an oil and gas banker for a bit, establish himself, get his MBA, and then, when he was in his 40s, would start his own company. He wasn't wrong about his future as an entrepreneur, but he was off by the timeline.

Johnson started Apartment Butler a few years ago when he saw how apartment communities had the potential to provide streamlined access to resident elected services — such as cleaning or pet care. At the same time, apartment communities across the U.S. were looking to beef up their amenities. Now, Apartment Butler is expanding to its third and fourth markets early next year and is looking to provide more services to its users.

Scott Parazynski, CEO of Fluidity Technologies

Scott Parazynski is a accomplished astronaut and surgeon, but he has a new career focus on drone operation. Courtesy of Fluidity

There are Renaissance men and then there's Scott Parazynski. He's has spent 57 days in space, trained as a trauma surgeon, and climbed Mount Everest as a team physician for the Discovery Channel. His latest conquest is designing a drone controller based on movement in space. The device, called the FT Aviator, allows for one-handed piloting of drones and has the potential to affect the way unmanned vehicles are piloted across industries. As the CEO of Fluidity Technologies, he has big plans for what one-handed drone operation can do.

David Grimes, CEO and co-founder of Snap Diligence

David Grimes thought he was creating a useful tool to vet colleagues. Turns out, he made a way for warm connections better than LinkedIn. Courtesy of Snap Diligence

Hell hath no fury like a businessman scorned. When a business partner ended up being a shady miscreant, David Grimes realized there wasn't a digital vetting tool where you can evaluate a potential associate. After thinking on the idea for a while, Grimes found a co-founder and a way to create an algorithm that can take public information and run it against a person. The company he created is called Snap Diligence.

Now, the tool has morphed into something else that's been unexpectedly in demand. Snap Diligence can find business connections through your already-established network of associates. It's this new feature the company is looking to expand in 2019.

What started as a way to protect your company from a sketchy business partner has turned into a digital networking tool. Getty Images

Houston software startup pivots to provide digital networking solutions

Several years ago, David Grimes had a business partner who played dirty. It wasn't until the trial that followed the business wrongdoing that Grimes discovered the man had a history of cheating companies out of money. Grimes envisioned a software service that used public information to research potential investors or associates before signing on the dotted line of a partnership.

"I wanted to find a tool that would alleviate that pain and that risk of doing business," Grimes says. "I couldn't find that tool."

When Grimes met private investigator, Daniel Weiss, at a Christmas party, he picked his brain about this idea of vetting business partners or investors. Turns out, that's exactly what Weiss did already. Together, the two co-founded Houston-based Snap Diligence, a software-as-a-service company that uses its custom algorithm to digitally investigate these potential associates.

The technology would data mine various public information avenues, such as Secretary of State documentation of business owners, managers, and directors, state district court records, and insurance records. It would look at all filings and legal cases of both the person and all the companies they have been associated with. It would even look at that person's contacts and see who you have in common and who you don't know about.

Unintended technology
Now that the tool the Grimes wanted finally existed, and Snap Diligence went into beta in April of 2017. The team reached out to all ages and industries to use the software. In January of 2018, they reconvened and looked at who was using the tool and how they were using it.

"They were mostly people in their 30s," Grimes says. "I didn't think they would have enough experience with risk to appreciate the tool. But what they were using it to connect to new opportunities."

Snap Diligence allowed the users to access new business connections and potential clients based on their already established networks.

"It's not LinkedIn where you sat next to your connection four years ago at a breakfast club," Grimes says. "This is information on people who are actually involved in a business together."

A banker approached Grimes and asked him to datamine all his clients to see all the potential business he could have by finding other companies a client is involved in but that doesn't yet use the bank for.

So, with this new tool, Snap Diligence pivoted about 3 to 4 months ago and now looks at first and second degree of existing relationships for the purpose of targeting new business clients.

"We started running this customer analysis work — and we had to rework our algorithm some — to spit out this batch mining process for customers and how you expand an existing customer relationship into a new opportunity," Grimes says.

The tool has been most popular with commercial insurance and commercial banking, Grimes says. Private equity has been a big player too, although it's not as big as a proponent since they have smaller client bases.

Growth plans on the horizon
The company has a few major clients coming in, Grimes says, and also expects to be able to mine third degree connections soon too. Snap Diligence operates in several states, but as more information is able to be pulled in, the tool will soon grow to more markets.

"SEC data is something we want to add fairly quickly, as well as real estate data," Grimes says. "The key is just importing more and more data that can further fill in the picture of someone's footprint."

With growth on the mind, Grimes recognizes that Houston has with venture and talent. Both are aspects the local innovation community has but needs more of.

"We have plenty of talent here in Houston, but it's harder to find the talent that doesn't mind going into a startup with the risk that comes with it," Grimes says. "Finding the right talent is difficult."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

3 Houston startups named most innovative in Texas by LexisNexis

report card

Three Houston companies claimed spots on LexisNexis's 10 Most Innovative Startups in Texas report, with two working in the geothermal energy space.

Sage Geosystems claimed the No. 3 spot on the list, and Fervo Energy followed closely behind at No. 5. Fintech unicorn HighRadius rounded out the list of Houston companies at No. 8.

LexisNexis Intellectual Property Solutions compiled the report. It was based on each company's Patent Asset Index, a proprietary metric from LexisNexis that identifies the strength and value of each company’s patent assets based on factors such as patent quality, geographic scope and size of the portfolio.

Houston tied with Austin, each with three companies represented on the list. Caris Life Sciences, a biotechnology company based in Dallas, claimed the top spot with a Patent Asset Index more than 5 times that of its next competitor, Apptronik, an Austin-based AI-powered humanoid robotics company.

“Texas has always been fertile ground for bold entrepreneurs, and these innovative startups carry that tradition forward with strong businesses based on outstanding patent assets,” Marco Richter, senior director of IP analytics and strategy for LexisNexis Intellectual Property Solutions, said in a release. “These companies have proven their innovation by creating the most valuable patent portfolios in a state that’s known for game-changing inventions and cutting-edge technologies.We are pleased to recognize Texas’ most innovative startups for turning their ideas into patented innovations and look forward to watching them scale, disrupt, and thrive on the foundation they’ve laid today.”

This year's list reflects a range in location and industry. Here's the full list of LexisNexis' 10 Most Innovative Startups in Texas, ranked by patent portfolios.

  1. Caris (Dallas)
  2. Apptronik (Austin)
  3. Sage Geosystems (Houston)
  4. HiddenLayer (Austin)
  5. Fervo Energy (Houston)
  6. Plus One Robotics (San Antonio)
  7. Diligent Robotics (Austin)
  8. HighRadius (Houston)
  9. LTK (Dallas)
  10. Eagle Eye Networks (Austin)

Sage Geosystems has partnered on major geothermal projects with the United States Department of Defense's Defense Innovation Unit, the U.S. Air Force and Meta Platforms. Sage's 3-megawatt commercial EarthStore geothermal energy storage facility in Christine, Texas, was expected to be completed by the end of last year.

Fervo Energy fully contracted its flagship 500 MW geothermal development, Cape Station, this spring. Cape Station is currently one of the world’s largest enhanced geothermal systems (EGS) developments, and the station will begin to deliver electricity to the grid in 2026. The company was recently named North American Company of the Year by research and consulting firm Cleantech Group and came in at No. 6 on Time magazine and Statista’s list of America’s Top GreenTech Companies of 2025. It's now considered a unicorn, meaning its valuation as a private company has surpassed $1 billion.

Meanwhile, HighRadius announced earlier this year that it plans to release a fully autonomous finance platform for the "office of the CFO" by 2027. The company reached unicorn status in 2020.

---

This article originally appeared on Energy Capital HTX.

UH student earns prestigious award for cancer vaccine research

up-and-comer

Cole Woody, a biology major in the College of Natural Sciences and Mathematics at the University of Houston, has been awarded a Barry Goldwater Scholarship, becoming the first sophomore in UH history to earn the prestigious prize for research in natural sciences, mathematics and engineering.

Woody was recognized for his research on developing potential cancer vaccines through chimeric RNAs. The work specifically investigates how a vaccine can more aggressively target cancers.

Woody developed the MHCole Pipeline, a bioinformatic tool that predicts peptide-HLA binding affinities with nearly 100 percent improvement in data processing efficiency. The MHCole Pipeline aims to find cancer-specific targets and develop personalized vaccines. Woody is also a junior research associate at the UH Sequencing Core and works in Dr. Steven Hsesheng Lin’s lab at MD Anderson Cancer Center.

“Cole’s work ethic and dedication are unmatched,” Preethi Gunaratne, director of the UH Sequencing Core and professor of Biology & Biochemistry at NSM, said in a news release. “He consistently worked 60 to 70 hours a week, committing himself to learning new techniques and coding the MHCole pipeline.”

Woody plans to earn his MD-PhD and has been accepted into the Harvard/MIT MD-PhD Early Access to Research Training (HEART) program. According to UH, recipients of the Goldwater Scholarship often go on to win various nationally prestigious awards.

"Cole’s ability to independently design and implement such a transformative tool at such an early stage in his career demonstrates his exceptional technical acumen and creative problem-solving skills, which should go a long way towards a promising career in immuno-oncology,” Gunaratne added in the release.

Houston founder on shaping the future of medicine through biotechnology and resilience

Guest Column

Living with chronic disease has shaped my life in profound ways. My journey began in 5th grade when I was diagnosed with Scheuermann’s disease, a degenerative disc condition that kept me sidelined for an entire year. Later, I was diagnosed with hereditary neuropathy with liability to pressure palsies (HNPP), a condition that significantly impacts nerve recovery. These experiences didn’t just challenge me physically, they reshaped my perspective on healthcare — and ultimately set me on my path to entrepreneurship. What started as personal health struggles evolved into a mission to transform patient care through innovative biotechnology.

A defining part of living with these conditions was the diagnostic process. I underwent nerve tests that involved electrical shocks to my hands and arms — without anesthesia — to measure nerve activity. The pain was intense, and each test left me thinking: There has to be a better way. Even in those difficult moments, I found myself thinking about how to improve the tools and processes used in healthcare.

HNPP, in particular, has been a frustrating condition. For most people, sleeping on an arm might cause temporary numbness that disappears in an hour. For me, that same numbness can last six months. Even more debilitating is the loss of strength and fine motor skills. Living with this reality forced me to take an active role in understanding my health and seeking solutions, a mindset that would later shape my approach to leadership.

Growing up in Houston, I was surrounded by innovation. My grandfather, a pioneering urologist, was among the first to introduce kidney dialysis in the city in the 1950s. His dedication to advancing patient care initially inspired me to pursue medicine. Though my path eventually led me to healthcare administration and eventually biotech, his influence instilled in me a lifelong commitment to medicine and making a difference.

Houston’s thriving medical and entrepreneurial ecosystems played a critical role in my journey. The city’s culture of innovation and collaboration provided opportunities to explore solutions to unmet medical needs. When I transitioned from healthcare administration to founding biotech companies, I drew on the same resilience I had developed while managing my own health challenges.

My experience with chronic disease also shaped my leadership philosophy. Rather than accepting diagnoses passively, I took a proactive approach questioning assumptions, collaborating with experts, and seeking new solutions. These same principles now guide decision-making at FibroBiologics, where we are committed to developing groundbreaking therapies that go beyond symptom management to address the root causes of disease.

The resilience I built through my health struggles has been invaluable in navigating business challenges. While my early career in healthcare administration provided industry insights, launching and leading companies required the same determination I had relied on in my personal health journey.

I believe the future of healthcare lies in curative treatments, not just symptom management. Fibroblast cells hold the promise of engaging the body’s own healing processes — the most powerful cure for chronic diseases. Cell therapy represents both a scientific breakthrough and a significant business opportunity, one that has the potential to improve patient outcomes while reducing long-term healthcare costs.

Innovation in medicine isn’t just about technology; it’s about reimagining what’s possible. The future of healthcare is being written today. At FibroBiologics, our mission is driven by more than just financial success. We are focused on making a meaningful impact on patients’ lives, and this purpose-driven approach helps attract talent, engage stakeholders, and differentiate in the marketplace. Aligning business goals with patient needs isn’t just the right thing to do, it’s a powerful model for sustainable growth and lasting innovation in biotech.

---

Pete O’Heeron is the CEO and founder of FibroBiologics, a Houston-based regenerative medicine company.